Zubsolv

Land: Europese Unie

Taal: Engels

Bron: EMA (European Medicines Agency)

Koop het nu

Bijsluiter Bijsluiter (PIL)
10-10-2023
Productkenmerken Productkenmerken (SPC)
10-10-2023

Werkstoffen:

Buprenorphine hydrochloride, Naloxone hydrochloride dihydrate

Beschikbaar vanaf:

Accord Healthcare S.L.U.

ATC-code:

N07BC51

INN (Algemene Internationale Benaming):

buprenorphine, naloxone

Therapeutische categorie:

Other nervous system drugs

Therapeutisch gebied:

Opioid-Related Disorders

therapeutische indicaties:

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment.The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

Product samenvatting:

Revision: 10

Autorisatie-status:

Authorised

Autorisatie datum:

2017-11-10

Bijsluiter

                                48
B. PACKAGE LEAFLET
49
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ZUBSOLV 0.7 MG/0.18 MG SUBLINGUAL TABLETS
ZUBSOLV 1.4 MG/0.36 MG SUBLINGUAL TABLETS
ZUBSOLV 2.9 MG/0.71 MG SUBLINGUAL TABLETS
ZUBSOLV 5.7 MG/1.4 MG SUBLINGUAL TABLETS
ZUBSOLV 8.6 MG/2.1 MG SUBLINGUAL TABLETS
ZUBSOLV 11.4 MG/2.9 MG SUBLINGUAL TABLETS
buprenorphine/naloxone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Zubsolv is and what it is used for
2.
What you need to know before you take Zubsolv
3.
How to take Zubsolv
4.
Possible side effects
5.
How to store Zubsolv
6.
Contents of the pack and other information
1.
WHAT ZUBSOLV IS AND WHAT IT IS USED FOR
Zubsolv contains the active substances buprenorphine and naloxone.
Zubsolv is used to treat
dependence on opioid (narcotic) drugs such as heroin or morphine in
drug addicts who have agreed
to be treated for their addiction. Zubsolv is used in adults and
adolescents over 15 years of age,
who are also receiving medical, social and psychological support.
HOW ZUBSOLV WORKS
The tablet contains buprenorphine which is responsible for the
treatment of opioid (narcotic)
dependence. It also contains naloxone which is used to deter
intravenous abuse of the product.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZUBSOLV
DO NOT TAKE ZUBSOLV
IF YOU:
-
are allergic to buprenorphine, naloxone or any of the other
ingredients of this medicine
(listed in section 6)
-
have SERIOUS BREATHING PROBLEMS
-
have
SERIOUS LIVER PROBLEMS
-
are intoxicated due to alcohol or have trembling, sweating, anxiety
                                
                                Lees het volledige document
                                
                            

Productkenmerken

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Zubsolv 0.7 mg/0.18 mg sublingual tablets
Zubsolv 1.4 mg/0.36 mg sublingual tablets
Zubsolv 2.9 mg/0.71 mg sublingual tablets
Zubsolv 5.7 mg/1.4 mg sublingual tablets
Zubsolv 8.6 mg/2.1 mg sublingual tablets
Zubsolv 11.4 mg/2.9 mg sublingual tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Zubsolv 0.7 mg/0.18 mg sublingual tablets
Each 0.7 mg/0.18 mg sublingual tablet contains 0.7 mg buprenorphine
(as hydrochloride) and
0.18 mg naloxone (as hydrochloride dihydrate).
Zubsolv 1.4 mg/0.36 mg sublingual tablets
Each 1.4 mg/0.36 mg sublingual tablet contains 1.4 mg buprenorphine
(as hydrochloride) and
0.36 mg naloxone (as hydrochloride dihydrate).
Zubsolv 2.9 mg/0.71 mg sublingual tablets
Each 2.9 mg/0.71 mg sublingual tablet contains 2.9 mg buprenorphine
(as hydrochloride) and
0.71 mg naloxone (as hydrochloride dihydrate).
Zubsolv 5.7 mg/1.4 mg sublingual tablets
Each 5.7 mg/1.4 mg sublingual tablet contains 5.7 mg buprenorphine (as
hydrochloride) and 1.4 mg
naloxone (as hydrochloride dihydrate).
Zubsolv 8.6 mg/2.1 mg sublingual tablets
Each 8.6 mg/2.1 mg sublingual tablet contains 8.6 mg buprenorphine (as
hydrochloride) and 2.1 mg
naloxone (as hydrochloride dihydrate).
Zubsolv 11.4 mg/2.9 mg sublingual tablets
Each 11.4 mg/2.9 mg sublingual tablet contains 11.4 mg buprenorphine
(as hydrochloride) and
2.9 mg naloxone (as hydrochloride dihydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Sublingual tablet
Zubsolv 0.7 mg/0.18 mg sublingual tablets
A white to off-white, oval tablet, length 6.8 mm and width 4.0 mm,
debossed with “.7” on one side.
Zubsolv 1.4 mg/0.36 mg sublingual tablets
A white to off-white, triangular tablet, base 7.2 mm and height 6.9
mm, debossed with “1.4” on one
3
side.
Zubsolv 2.9 mg/0.71 mg sublingual tablets
A white to off-white, D-shaped tablet, height 7.3 mm and width 5.65
mm, debossed with “2.9” on
one side.
Zubsolv 5.7 mg/1.4 mg sublingual tablets
A white to off-whit
                                
                                Lees het volledige document
                                
                            

Documenten in andere talen

Bijsluiter Bijsluiter Bulgaars 10-10-2023
Productkenmerken Productkenmerken Bulgaars 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Bulgaars 12-01-2018
Bijsluiter Bijsluiter Spaans 10-10-2023
Productkenmerken Productkenmerken Spaans 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Spaans 12-01-2018
Bijsluiter Bijsluiter Tsjechisch 10-10-2023
Productkenmerken Productkenmerken Tsjechisch 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Tsjechisch 12-01-2018
Bijsluiter Bijsluiter Deens 10-10-2023
Productkenmerken Productkenmerken Deens 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Deens 12-01-2018
Bijsluiter Bijsluiter Duits 10-10-2023
Productkenmerken Productkenmerken Duits 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Duits 12-01-2018
Bijsluiter Bijsluiter Estlands 10-10-2023
Productkenmerken Productkenmerken Estlands 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Estlands 12-01-2018
Bijsluiter Bijsluiter Grieks 10-10-2023
Productkenmerken Productkenmerken Grieks 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Grieks 12-01-2018
Bijsluiter Bijsluiter Frans 10-10-2023
Productkenmerken Productkenmerken Frans 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Frans 12-01-2018
Bijsluiter Bijsluiter Italiaans 10-10-2023
Productkenmerken Productkenmerken Italiaans 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Italiaans 12-01-2018
Bijsluiter Bijsluiter Letlands 10-10-2023
Productkenmerken Productkenmerken Letlands 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Letlands 12-01-2018
Bijsluiter Bijsluiter Litouws 10-10-2023
Productkenmerken Productkenmerken Litouws 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Litouws 12-01-2018
Bijsluiter Bijsluiter Hongaars 10-10-2023
Productkenmerken Productkenmerken Hongaars 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Hongaars 12-01-2018
Bijsluiter Bijsluiter Maltees 10-10-2023
Productkenmerken Productkenmerken Maltees 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Maltees 12-01-2018
Bijsluiter Bijsluiter Nederlands 10-10-2023
Productkenmerken Productkenmerken Nederlands 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Nederlands 12-01-2018
Bijsluiter Bijsluiter Pools 10-10-2023
Productkenmerken Productkenmerken Pools 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Pools 12-01-2018
Bijsluiter Bijsluiter Portugees 10-10-2023
Productkenmerken Productkenmerken Portugees 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Portugees 12-01-2018
Bijsluiter Bijsluiter Roemeens 10-10-2023
Productkenmerken Productkenmerken Roemeens 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Roemeens 12-01-2018
Bijsluiter Bijsluiter Slowaaks 10-10-2023
Productkenmerken Productkenmerken Slowaaks 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Slowaaks 12-01-2018
Bijsluiter Bijsluiter Sloveens 10-10-2023
Productkenmerken Productkenmerken Sloveens 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Sloveens 12-01-2018
Bijsluiter Bijsluiter Fins 10-10-2023
Productkenmerken Productkenmerken Fins 10-10-2023
Bijsluiter Bijsluiter Zweeds 10-10-2023
Productkenmerken Productkenmerken Zweeds 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Zweeds 12-01-2018
Bijsluiter Bijsluiter Noors 10-10-2023
Productkenmerken Productkenmerken Noors 10-10-2023
Bijsluiter Bijsluiter IJslands 10-10-2023
Productkenmerken Productkenmerken IJslands 10-10-2023
Bijsluiter Bijsluiter Kroatisch 10-10-2023
Productkenmerken Productkenmerken Kroatisch 10-10-2023
Openbaar beoordelingsrapport Openbaar beoordelingsrapport Kroatisch 12-01-2018

Bekijk de geschiedenis van documenten